Acute exacerbations of chronic bronchitis in elderly patients: Pathogenesis, diagnosis and management

Drugs and Aging

Volumn 24, Issue 7, 2007, Pages 555-572

  Hayes Jr , Don ^a   Meyer, Keith C ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

AGING; BACTERIAL VIRULENCE; CD8+ T LYMPHOCYTE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; DRUG RESISTANCE; DUST; ELDERLY CARE; ENVIRONMENTAL FACTOR; HAEMOPHILUS INFLUENZAE; HEALTH STATUS; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; IMMUNE RESPONSE; IMMUNITY; LUNG FUNCTION; LUNG STRUCTURE; MORAXELLA CATARRHALIS; OUTPATIENT; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE;

AGED; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BRONCHITIS, CHRONIC; DISEASE PROGRESSION; FLUOROQUINOLONES; HEALTH SERVICES FOR THE AGED; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VIRUS DISEASES;

EID: 34547570537     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724070-00004     Document Type: Review

References (143)

1. Petty TL. Definitions in chronic obstructive pulmonary disease. Clin Chest Med 1990; 11 (3): 363-73
2. Anto JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17 (5): 982-94
3. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117 (2 Suppl.): 1-4S
4. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123 (5): 1684-92
5. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163 (5): 1256-76
6. Fabbri LM, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22 (1): 1-2
7. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932-46
8. Sterk PJ. Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J 2004 Apr; 23 (4): 497-8
9. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136 (1): 225-44
10. British Thoracic Society. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. Thoracic 1997; Suppl. 5: S1-28
11. Engström CP, Persson LO, Larsson S, et al. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001; 18 (1): 69-76
12. Petty TL. Scope of the COPD problem in North America. Chest 2000; 117: 326S-31S
13. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003; Suppl. C: S3-14
14. Meyer KC. Aging. Proc Am Thorac Soc 2005; 2 (5): 433-9
15. Peterson DD, Fishman AP. The lungs in later life. In: Fishman AP, editor. Pulmonary disease and disorders: update 1. New York: McGraw-Hill, 1982: 123-36
16. Enright PL, Kronmal RA, Manolio TA, et al. Respiratory muscle strength in the elderly: correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 149 (2 Pt 1): 430-8
17. Peterson DD, Pack AI, Silage DA, et al. Effects of aging on ventilatory and occlusion pressure responses to hypoxia and hypercapnia. Am Rev Respir Dis 1981; 124 (4): 387-91
18. Tack M, Altose MD, Cherniack NS. Effect of aging on the perception of resistive ventilatory loads. Am Rev Respir Dis 1982; 126 (3): 463-7
19. Ancoli-Israel S, Coy T. Are breathing disturbances in elderly equivalent to sleep apnea syndrome? Sleep 1994; 17 (1): 77-83
20. Delves PJ, Roitt IM. The immune system: first of two parts. N Engl J Med 2000; 343 (1): 37-49
21. Delves PJ, Roitt IM. The immune system: second of two parts. N Engl J Med 2000; 343 (2): 108-17
22. Medzhitov R, Janeway Jr C. Innate immunity. N Engl J Med 2000; 343 (5): 338-44
23. Zhang P, Summer WR, Bagby GJ, et al. Innate immunity and pulmonary host defense. Immunol Rev 2000; 173: 39-51
24. Masten BJ. Initiation of lung immunity: the afferent limb and the role of dendritic cells. Semin Respir Crit Care Med 2004; 25 (1): 11-20
25. Ginaldi L, De Martinis M, D'Ostilio A, et al. Immunological changes in the elderly. Aging Clin Exp Res 1999; 11: 281-6
26. Meyer KC. The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol 2001; 128 (1): 23-31
27. Nicoletti C, Borghesi-Nicoletti C, Yang XH, et al. Repertoire diversity of antibody response to bacterial antigens in aged mice: II. Phosphorylcholine-antibody in young and aged mice differ in both VH/VL gene repertoire and in specificity. J Immunol 1991 Oct 15; 147 (8): 2750-5
28. Liu J, Wang S, Liu H, et al. The monitoring biomarker for immune function of lymphocytes in the elderly. Mech Ageing Dev 1997; 94 (1-3): 177-82
29. Song H, Price PW, Cerny J. Age-related changes in antibody repertoire: contribution from T cells. Immunol Rev 1997; 160: 55-62
30. Flurkey K, Stadecker M, Miller RA. Memory T lymphocyte hyporesponsiveness to non-cognate stimuli: a key factor in age-related immunodeficiency. Eur J Immunol 1992; 22 (4): 931-5
31. Li SP, Verma S, Miller RA. Age-related defects in T cell expression of CD40 ligand and induction of in vitro B cell activation. Aging Immunol Infect Dis 1995; 6: 79-93
32. Cakman I, Rohwer J, Schutz RM, et al. Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev 1996; 87 (3): 197-209
33. Zhou T, Edwards 3rd CK, Mountz JD. Prevention of age-related T cell apoptosis defect in CD2-fas-transgenic mice. J Exp Med 1995; 182 (1): 129-37
34. Jackola DR, Ruger JK, Miller RA. Age-associated changes in human T cell phenotype and function. Aging (Milano) 1994; 6 (1): 25-34
35. Linton PJ, Haynes L, Tsui L, et al. From naive to effector: alterations with aging. Immunol Rev 1997; 160: 9-18
36. Miller RA, Garcia G, Kirk CJ, et al. Early activation defects in T lymphocytes from aged mice. Immunol Rev 1997; 160: 79-90
37. Feldman C. Pneumonia in the elderly. Clin Chest Med 1999; 20 (3): 563-73
38. Kim WD, Kim WS, Koh Y, et al. Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest 2002; 122 (2): 437-44
39. Costabel U, Maier K, Teschler H, et al. Local immune components in chronic obstructive pulmonary disease. Respiration 1992; 59 Suppl. 1: 17-9
40. Robbins CS, Dawe DE, Goncharova SI, et al. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. Am J Respir Cell Mol Biol 2004; 30 (2): 202-11
41. Schleimer RP. Innate immune responses and chronic obstructive pulmonary disease: "Terminator" or "Terminator 2"? Proc Am Thorac Soc 2005; 2 (4): 342-6; discussion 371-2
42. Sabroe I, Parker LC, Dockrell DH, et al. Targeting the networks that underpin contiguous immunity in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175 (4): 306-11
43. Pons J, Sauleda J, Regueiro V, et al. Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respir Res 2006; 7 (1): 64
44. Marc MM, Korosec P, Kosnik M, et al. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol 2004; 31 (2): 216-9
45. Kosmas EN, Zorpidou D, Vassilareas V, et al. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest 1997; 112 (2): 341-7
46. Guo X, Lin HM, Lin Z, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J 2001; 18 (3): 482-90
47. Yang IA, Seeney SL, Wolter JM, et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun 2003; 4 (4): 269-74
48. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59 (7): 574-80
49. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170 (7): 760-5
50. Mullen JB, Wright JL, Wiggs BR, et al. Reassessment of inflammation of airways in chronic bronchitis. BMJ (Clin Res Ed) 1985; 291 (6504): 1235-9
51. Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147 (2): 301-6
52. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155 (3): 852-7
53. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153 (2): 530-4
54. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112 (2): 505-10
55. Beeh KM, Beier J, Kornmann O, et al. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003; 123 (3): 778-83
56. Mueller R, Chanez P, Campbell AM, et al. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 1996; 90 (2): 79-85
57. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160 (3): 893-8
58. Meyer KC, Rosenthal NS, Soergel P, et al. Neutrophils and low-grade inflammation in the seemingly normal aging human lung. Mech Ageing Dev 1998; 104 (2): 169-81
59. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28 (1): 219-42
60. Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 2004; 18 (15): 1897-9
61. Rogers DF. Airway goblet cells: responsive and adaptable frontline defenders. Eur Respir J 1994; 7 (9): 1690-706
62. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999 Nov; 160 (5 Pt 2): S49-52
63. Wright JL, Lawson L, Pare PD, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease: the effect of oxygen and exercise. Am Rev Respir Dis 1983; 128 (4): 702-7
64. Peinado VI, Barbera JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (5 Pt 1): 1605-11
65. Riley DJ, Thakker-Varia S, Poiani GJ, et al. Vascular remodeling. In: Crystal RG, West JB, Barnes PJ, et al., editors. The lung: scientific foundations. Philadelphia (PA): Lippincott-Raven, 1977: 1589-97
66. Wanner A. The role of mucus in chronic obstructive pulmonary disease. Chest 1990; 97 (2 Suppl.): 11-15S
67. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease: part one. Am J Respir Crit Care Med 1994; 150 (3): 833-52
68. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease: part two. Am J Respir Crit Care Med 1994; 150 (4): 1158-68
69. Pelkonen M, Notkola IL, Nissinen A, et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130 (4): 1129-37
70. Ganrot PO, Laurell CB, Eriksson S. Obstructive lung disease and trypsin inhibitors in alpha-1-antitrypsin deficiency. Scand J Clin Lab Invest 1967; 19 (3): 205-8
71. Carette MF, Mayaud C, Valade S, et al. Pulmonary emphysema, hepatic lesions, and insulin-dependent diabetes in a patient with alpha-1-antitrypsin (Pi ZZ) deficiency (author's transl) [in French]. Ann Med Interne (Paris) 1980; 131 (6): 349-52
72. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol 1998; 18 (5): 670-4
73. Stein CE, Kumaran K, Fall CH, et al. Relation of fetal growth to adult lung function in south India. Thorax 1997; 52 (10): 895-9
74. Todisco T, de Benedictis FM, Iannacci L, et al. Mild prematurity and respiratory functions. Eur J Pediatr 1993; 152 (1): 55-8
75. Tager IB, Segal MR, Speizer FE, et al. The natural history of forced expiratory volumes: effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988; 138 (4): 837-49
76. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80 (3): 501-22
77. US Department of Health and Human Services. The health consequences of smoking: what it means to you. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004 [online]. Available from URL: http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2004/ 00_pdfs/SGR2004_Whatitmeanstoyou.pdf [Accessed 2007 Jul 4]
78. DeMeo DL, Silverman EK. Genetics of chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2003; 24 (2): 151-60
79. Leuenberger P, Schwartz J, Ackermann-Liebrich U, et al. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA study): Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med 1994; 150 (5 Pt 1): 1222-8
80. Dayal HH, Khuder S, Sharrar R, et al. Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ Res 1994; 65 (2): 161-71
81. Kauffmann F, Drouet D, Lellouch J, et al. Twelve years spirometric changes among Paris area workers. Int J Epidemiol 1979; 8 (3): 201-12
82. Pandey MR. Prevalence of chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax 1984; 39 (5): 331-6
83. Pandey MR. Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax 1984; 39 (5): 337-9
84. Behera D, Jindal SK. Respiratory symptoms in Indian women using domestic cooking fuels. Chest 1991; 100 (2): 385-8
85. Perez-Padilla R, Regalado J, Vedal S, et al. Exposure to biomass smoke and chronic airway disease in Mexican women: a case-control study. Am J Respir Crit Care Med 1996; 154 (3 Pt 1): 701-6
86. Dennis RJ, Maldonado D, Norman S, et al. Woodsmoke exposure and risk for obstructive airways disease among women. Chest 1996; 109 (1): 115-9
87. Peabody JW, Riddell TJ, Smith KR, et al. Indoor air pollution in rural China: cooking fuels, stoves, and health status. Arch Environ Occup Health 2005; 60 (2): 86-95
88. Hogg JC. Childhood viral infection and the pathogenesis of asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 1999; 160 (5 Pt 2): S26-8
89. Johnston ID. Effect of pneumonia in childhood on adult lung function. J Pediatr 1999; 135 (2 Pt 2): 33-7
90. Shaheen SO, Barker DJ, Holgate ST. Do lower respiratory tract infections in early childhood cause chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1995; 151 (5): 1649-51; discussion 1651-2
91. Welle I, Eide GE, Gulsvik A, et al. Pulmonary gas exchange and educational level: a community study. Eur Respir J 2004; 23 (4): 583-8
92. Koster A, Bosma H, Kempen GI, et al. Socioeconomic inequalities in mobility decline in chronic disease groups (asthma/COPD, heart disease, diabetes mellitus, low back pain): only minor role for disease severity and comorbidity. J Epidemiol Community Health 2004; 58 (10): 862-9
93. Power C, Hypponen E, Smith GD. Socioeconomic position in childhood and early adult life and risk of mortality: a prospective study of the mothers of the 1958 British birth cohort. Am Public Health 2005; 95 (8): 1396-402
94. Mathers CD, Bernard C, Iburg KM, et al. World Health Organization: global burden of disease in 2002: data sources, methods and results [online]. Available from URL: http://www.who.int/healthinfo/paper54.pdf [Accessed 2006 Nov 20]
95. Mathers CD, Loncar D. Updated projections of global mortality and burden of disease, 2002-2030: data sources, methods and results [online]. Available from URL: http://www.who.int/healthinfo/statistics/bodprojectionspaper.pdf [Accessed 2006 Nov 20]
96. Miravitlles M, Murio C, Guerrero T, et al. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123 (3): 784-91
97. Executive summary: gold strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2005 [online]. Available from URL: http://goldcopd.com/Guidelineitem.asp?.l1 = 2&l2 = 1&intId = 996 [Accessed 2006 Nov 20]
98. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272 (19): 1497-505
99. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340 (25): 1948-53
100. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353 (9167): 1819-23
101. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343 (26): 1902-9
102. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320 (7245): 1297-303
103. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: American Thoracic Society. Am J Respir Crit Care Med 1995; 152 (5 Pt 2): S77-121
104. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273 (12): 957-60
105. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106 (2): 196-204
106. Martinez FJ. Acute exacerbations of chronic bronchitis: diagnosis and therapy. J Clin Outcomes Manage 2004; 11: 659-73
107. Connolly MJ, Lowe D, Anstey K, et al. Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organization. Thorax 2006; 61: 843-8
108. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398-401S
109. Ball P. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61-8
110. Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10 Suppl. B: 3-32B
111. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117 Suppl. 2: 380-385S
112. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152 (4 Pt 1): 1316-20
113. Pela R, Marchesani F, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53 (3): 262-7
114. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1498-505
115. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD: Study Group of Bacterial Infection in COPD. Chest 1999; 116 (1): 40-6
116. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113 (6): 1542-8
117. Blasi F, Tarsia P, Aliberti S. Strategic targets of essential host- pathogen interactions. Respiration 2005; 72 (1): 9-25
118. Berenson CS, Murphy TF, Wrona CT, et al. Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines. Infect Immun 2005; 73: 2728-35
119. Shuto T, Xu H, Wang B, et al. Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha/beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci U S A 2001; 98: 8774-9
120. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 71-8
121. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112 (6 Suppl.): 310-313S
122. O'Donnell DE, Hernandez P, Aaron S, et al. Canadian Thoracic Society COPD guidelines: summary of highlights for family doctors [in French]. Can Respir J 2003; 10 (6): 316-9
123. Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15: 59-70
124. Murphy TF, Sethi S. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient. Drugs Aging 2002; 19: 761-75
125. Adams SG, Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15: 234-47
126. Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am J Med 2001; 111: 4-12S
127. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125 (3): 953-64
128. Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005; 25 (6): 1001-10
129. Destache CJ, Dewan N, O'Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43 Suppl. A: 107-13
130. Doll H, Grey-Amante P, Duprat-Lomon I, et al. Quality of life in acute exacerbation of chronic bronchitis: results from a German population study. Respir Med 2002; 96 (1): 39-51
131. Meyer KC. Lung infections and aging. Ageing Res Rev 2004; 3 (1): 55-67
132. Neralla S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Drugs Aging 2004; 21 (13): 851-64
133. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38 (8): 843-53
134. Snow V, Lascher S, Mottur-Pilson C, et al. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134 (7): 595-9
135. Pea F, Pavan F, Lugatti E, et al. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Clin Pharmacokinet 2006; 45 (3): 287-95
136. Sin DD, Tu JV. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonry disease. Can Respir J 2000; 7 (6): 466-71
137. Sullivan JT, Lettieri JT, Liu P, et al. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet 2001; 40 Suppl. 1: 11-8
138. Cazzola M, Matera MG, Donnarumma G, et al. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. Chest 2005; 128 (4): 2093-8
139. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61 (9): 772-8
140. Paz-Diaz H, Montes de Oca M, Lopez JM, et al. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil 2007; 86 (1): 30-6
141. Poole PJ, Chacko E, Wood-Baker RW, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (1): CD002733
142. Wang CS, Wang ST, Lai CT, et al. Impact of influenza vaccination on major cause-specific mortality. Vaccine 2007 Jan 26; 25 (7): 1196-203
143. Granger R, Walters J, Poole PJ, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (4): CD001390